Trial Profile
A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Coronavirus vaccine Takis (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Takis
- 01 Mar 2023 Results from the phase 1, assessing safety and immunogenicity of COVID-eVax, published in the Molecular Therapy
- 10 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 20 Dec 2021 Status changed from recruiting to active, no longer recruiting.